Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

NCT04030455 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Laryngeal Squamous Cell Carcinoma
Stage II Laryngeal Cancer AJCC v8
Stage III Laryngeal Cancer AJCC v8

Interventions

DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Docetaxel
BIOLOGICAL: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]